Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.08
PCRX's Cash-to-Debt is ranked lower than
59% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. PCRX: 1.08 )
Ranked among companies with meaningful Cash-to-Debt only.
PCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.49 Max: No Debt
Current: 1.08
Equity-to-Asset 0.44
PCRX's Equity-to-Asset is ranked lower than
77% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. PCRX: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
PCRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.82  Med: 0.43 Max: 0.66
Current: 0.44
-0.82
0.66
Debt-to-Equity 1.03
PCRX's Debt-to-Equity is ranked lower than
85% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. PCRX: 1.03 )
Ranked among companies with meaningful Debt-to-Equity only.
PCRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.29  Med: 0.59 Max: 2.8
Current: 1.03
-1.29
2.8
Debt-to-EBITDA -10.42
PCRX's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. PCRX: -10.42 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PCRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.42  Med: -0.75 Max: 21.67
Current: -10.42
-10.42
21.67
Piotroski F-Score: 4
Altman Z-Score: 2.83
Beneish M-Score: -2.78
WACC vs ROIC
13.03%
-20.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -12.79
PCRX's Operating Margin % is ranked lower than
79% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. PCRX: -12.79 )
Ranked among companies with meaningful Operating Margin % only.
PCRX' s Operating Margin % Range Over the Past 10 Years
Min: -325.77  Med: -126.13 Max: 3.8
Current: -12.79
-325.77
3.8
Net Margin % -18.25
PCRX's Net Margin % is ranked lower than
80% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. PCRX: -18.25 )
Ranked among companies with meaningful Net Margin % only.
PCRX' s Net Margin % Range Over the Past 10 Years
Min: -300.62  Med: -133.77 Max: 0.75
Current: -18.25
-300.62
0.75
ROE % -20.81
PCRX's ROE % is ranked lower than
81% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. PCRX: -20.81 )
Ranked among companies with meaningful ROE % only.
PCRX' s ROE % Range Over the Past 10 Years
Min: -558.91  Med: -54.49 Max: 0.95
Current: -20.81
-558.91
0.95
ROA % -9.90
PCRX's ROA % is ranked lower than
79% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. PCRX: -9.90 )
Ranked among companies with meaningful ROA % only.
PCRX' s ROA % Range Over the Past 10 Years
Min: -82.83  Med: -46.36 Max: 0.52
Current: -9.9
-82.83
0.52
ROC (Joel Greenblatt) % -31.74
PCRX's ROC (Joel Greenblatt) % is ranked lower than
79% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. PCRX: -31.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PCRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -251.5  Med: -116.71 Max: 8.96
Current: -31.74
-251.5
8.96
3-Year Revenue Growth Rate 42.30
PCRX's 3-Year Revenue Growth Rate is ranked higher than
96% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. PCRX: 42.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PCRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -66.9  Med: -5.5 Max: 80.4
Current: 42.3
-66.9
80.4
3-Year EBITDA Growth Rate -34.20
PCRX's 3-Year EBITDA Growth Rate is ranked lower than
95% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. PCRX: -34.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PCRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.2  Med: -65.15 Max: -34.2
Current: -34.2
-70.2
-34.2
3-Year EPS without NRI Growth Rate -19.10
PCRX's 3-Year EPS without NRI Growth Rate is ranked lower than
82% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. PCRX: -19.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PCRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.6  Med: -65.6 Max: -19.1
Current: -19.1
-68.6
-19.1
GuruFocus has detected 1 Warning Sign with Pacira Pharmaceuticals Inc PCRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PCRX's 30-Y Financials

Financials (Next Earnings Date: 2018-03-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

PCRX Guru Trades in Q4 2016

Ron Baron 24,255 sh (+10.65%)
Jim Simons 25,200 sh (+1.61%)
Ken Fisher Sold Out
Mariko Gordon 1,219,642 sh (-0.03%)
» More
Q1 2017

PCRX Guru Trades in Q1 2017

Paul Tudor Jones 501,470 sh (New)
Steven Cohen 70,000 sh (New)
Ken Fisher 6,257 sh (New)
Ron Baron 49,134 sh (+102.57%)
Jim Simons Sold Out
Mariko Gordon 1,158,699 sh (-5.00%)
» More
Q2 2017

PCRX Guru Trades in Q2 2017

Jim Simons 17,800 sh (New)
Eaton Vance Worldwide Health Sciences Fund 128,246 sh (New)
Steven Cohen 170,200 sh (+143.14%)
Ron Baron 72,334 sh (+47.22%)
Ken Fisher 6,257 sh (unchged)
Mariko Gordon 1,121,925 sh (-3.17%)
Paul Tudor Jones 4,887 sh (-99.03%)
» More
Q3 2017

PCRX Guru Trades in Q3 2017

Jim Simons 374,500 sh (+2003.93%)
Steven Cohen 1,084,886 sh (+537.42%)
Mariko Gordon 1,222,655 sh (+8.98%)
Eaton Vance Worldwide Health Sciences Fund 205,136 sh (+59.96%)
Steven Cohen 782,200 sh (unchged)
Ron Baron Sold Out
Paul Tudor Jones Sold Out
Ken Fisher Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2017-09-30 Add 8.98%0.24%$35.7 - $50.45 $ 45.9514%1,222,655
Ron Baron 2017-09-30 Sold Out 0.02%$35.7 - $50.45 $ 45.9514%0
Ken Fisher 2017-09-30 Sold Out $35.7 - $50.45 $ 45.9514%0
Mariko Gordon 2017-06-30 Reduce -3.17%0.1%$42.2 - $51.7 $ 45.95-1%1,121,925
Ron Baron 2017-06-30 Add 47.22%0.01%$42.2 - $51.7 $ 45.95-1%72,334
Mariko Gordon 2017-03-31 Reduce -5.00%0.11%$34.15 - $50.45 $ 45.956%1,158,699
Ron Baron 2017-03-31 Add 102.57%0.01%$34.15 - $50.45 $ 45.956%49,134
Ken Fisher 2017-03-31 New Buy$34.15 - $50.45 $ 45.956%6,257
Mariko Gordon 2016-12-31 Reduce -0.03%$30.25 - $37.6 $ 45.9538%1,219,642
Ron Baron 2016-12-31 Add 10.65%$30.25 - $37.6 $ 45.9538%24,255
Ken Fisher 2016-12-31 Sold Out $30.25 - $37.6 $ 45.9538%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:TSE:8129, TSE:4547, NAS:ENDP, SZSE:002435, HKSE:02005, SZSE:300401, NAS:IPXL, SHSE:600812, NAS:RDUS, SHSE:600750, SZSE:300194, NYSE:DPLO, SHSE:600993, SZSE:300630, BOM:532872, BOM:533573, SZSE:002737, XKRX:145020, BOM:540596, SHSE:600557 » details
Traded in other countries:82P.Germany,
Headquarter Location:USA
Pacira Pharmaceuticals Inc is a specialty and generic drug manufacturing company. The company develops, manufactures, and commercializes pharmaceutical products for use in hospitals and ambulatory surgery centers across the United States.

Pacira Pharmaceuticals is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and commercialization of pharmaceutical products, primarily for use in hospitals and ambulatory surgery centers. The company focuses its product candidates within the United States, and intends to out-license commercialization rights for other territories. Pacira aims to retain significant control over the development process and commercial execution for its product candidates.

Guru Investment Theses on Pacira Pharmaceuticals Inc

Baron Funds Comments on PaciraPharmaceuticals - Jan 18, 2017

Other companies we favor have wrapped intellectual property around an already proven pharmaceutical to create a new, protected franchise. The risk of not receiving approval for such products is significantly lower than for a typical bio-pharma investment. An example is PaciraPharmaceuticals, Inc. (NASDAQ:PCRX), whose FDA-approved medication is comprised of the pain killer bupivacaine combined with proprietary IP called Depo-Foam that enables its timed release. The product is appealing as it can in many cases eliminate the need for post-operative opiates and result in a shorter hospital stay.



From Baron Discovery Fund's Investing in Earlier Stage Small Cap Growth Companies January 2017.



Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals - Aug 10, 2016

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells an injectable drug for local post-surgical analgesia (localized pain relief) called EXPAREL. In the fourth quarter of 2015, Pacira reached a very favorable resolution with the FDA concerning certain issues which had previously impeded its ability to market its drug to hospital customers. We re-established our investment in the company in the third quarter of 2015 as it appeared from public reports that the company was making significant progress on this front (and the FDA removed the warning letter from its site in September). Shares have been weak in the second quarter of 2016 as Pacira has not yet seen a re-acceleration in the growth of the drug (management has always guided to a late 2016 effect). In our opinion, Pacira still retains its large multi-billion dollar market opportunity, and we should start to see accelerating revenues by year-end.



From Baron Discovery Fund's second quarter 2016 commentary.





Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals Inc. - May 19, 2016

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells a drug for local surgical analgesia (an anesthetic) called EXPAREL. At the end of the third quarter of 2015, Pacira received a favorable resolution of certain FDA issues, and we re-established our investment at the lower levels caused by the prior regulatory uncertainty. In our opinion, shares were down in the first quarter due to the general negative industry dynamics around pharmaceutical companies.



From the Baron Global Advantage Fund first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals Inc. - Feb 25, 2016

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells a long-lasting pain medication called EXPAREL. This is an approved drug for local surgical analgesia (an anesthetic) that can be used for a multitude of soft tissue and orthopedic procedures. Ultimately, we believe that Pacira will obtain a nerve block indication for the drug as well. Effectively, Pacira has taken a generic drug called bupivacaine (under use for decades) and wrapped it with a special time release coating that allows analgesic effects to last for up to three days instead of just hours. This saves money for the health care system by allowing for earlier release of patients and much lower use of dangerous opioid pain killers. This wrapper technology can be used for other drugs, and the company is developing a number of these which could bring additional upside to valuation. We were prior owners of Pacira, but sold the investment at much higher levels when we grew concerned about regulatory issues with the FDA that cropped up at the end of 2014. Shares dropped considerable after that. By the end of the third quarter, we anticipated a favorable resolution of these issues after the FDA removed the warning letter from its website (a highly unusual event), and we re-established our investment at the lower levels caused by the regulatory uncertainty. In the fourth quarter, Pacira resolved all of its marketing issues with the FDA via a formal agreement. This could allow for accelerated growth in 2016. Run rate sales of EXPAREL are now about $250 million and the market could be worth billions. Pacira has the potential for years of continued growth.



From Baron Discover Fund's fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Pacira Pharmaceuticals Inc

Pacira Announces FDA Advisory Committee Meeting to Review sNDA for EXPAREL® as a Nerve Block for Regional Analgesia
Pacira Pharmaceuticals to Present at Two November Healthcare Conferences
Pacira Pharmaceuticals Announces Timing for Third Quarter 2017 Financial Results Webcast and Conference Call
Pacira Pharmaceuticals Announces FDA Acceptance of sNDA for EXPAREL as a Nerve Block to Produce Regional Analgesia
Steven Cohen Doubles Down on Sickle Cell Disease Therapeutics Company Global Blood Guru adds approximately 225% to the position
On Oct. 2, Steven Cohen (Trades, Portfolio) increased his Global Blood Therapeutics Inc. (NASDAQ:GBT) position, according to GuruFocus real-time picks. Read more...
Pacira Pharmaceuticals CEO to Testify at White House Opioid Crisis Commission Meeting
New Research: Overprescribing of Postsurgical Opioids Poses a Serious Threat to Patients and their Communities; Women Undergoing Surgery are at Greatest Risk
Pacira Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
Steven Cohen Dives Into Array BioPharma Guru keeps adding to positions in health care industry
On Sept. 11, Point72 manager Steven Cohen (Trades, Portfolio) invested in 6,766,507 shares of Array BioPharma Inc. (NASDAQ:ARRY), according to GuruFocus real-time picks. With this transaction, the guru increased his position 281.23%. Read more...
Pacira Pharmaceuticals, Aetna, and the American Association of Oral and Maxillofacial Surgeons Join Together in a Program to Reduce Opioid Exposure for Patients Undergoing Wisdom Tooth Extraction

Ratios

vs
industry
vs
history
Forward PE Ratio 82.64
PCRX's Forward PE Ratio is ranked lower than
85% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. PCRX: 82.64 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 7.05
PCRX's PB Ratio is ranked lower than
78% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. PCRX: 7.05 )
Ranked among companies with meaningful PB Ratio only.
PCRX' s PB Ratio Range Over the Past 10 Years
Min: 3.47  Med: 8.97 Max: 73.42
Current: 7.05
3.47
73.42
PS Ratio 6.43
PCRX's PS Ratio is ranked lower than
66% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. PCRX: 6.43 )
Ranked among companies with meaningful PS Ratio only.
PCRX' s PS Ratio Range Over the Past 10 Years
Min: 0.39  Med: 11.1 Max: 30.46
Current: 6.43
0.39
30.46
Price-to-Operating-Cash-Flow 94.70
PCRX's Price-to-Operating-Cash-Flow is ranked lower than
86% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. PCRX: 94.70 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PCRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 33.8  Med: 76.61 Max: 894.45
Current: 94.7
33.8
894.45
EV-to-EBIT -46.50
PCRX's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. PCRX: -46.50 )
Ranked among companies with meaningful EV-to-EBIT only.
PCRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -794  Med: -14.9 Max: 543.4
Current: -46.5
-794
543.4
EV-to-EBITDA -70.32
PCRX's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. PCRX: -70.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
PCRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -200.5  Med: -11.8 Max: 876.1
Current: -70.32
-200.5
876.1
EV-to-Revenue 6.56
PCRX's EV-to-Revenue is ranked lower than
64% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. PCRX: 6.56 )
Ranked among companies with meaningful EV-to-Revenue only.
PCRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.5  Med: 12.4 Max: 31
Current: 6.56
2.5
31
Current Ratio 6.99
PCRX's Current Ratio is ranked higher than
85% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. PCRX: 6.99 )
Ranked among companies with meaningful Current Ratio only.
PCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.71 Max: 10.16
Current: 6.99
0.81
10.16
Quick Ratio 6.24
PCRX's Quick Ratio is ranked higher than
86% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. PCRX: 6.24 )
Ranked among companies with meaningful Quick Ratio only.
PCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.43 Max: 9.31
Current: 6.24
0.68
9.31
Days Inventory 138.96
PCRX's Days Inventory is ranked lower than
52% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. PCRX: 138.96 )
Ranked among companies with meaningful Days Inventory only.
PCRX' s Days Inventory Range Over the Past 10 Years
Min: 31.07  Med: 75.65 Max: 230.95
Current: 138.96
31.07
230.95
Days Sales Outstanding 35.17
PCRX's Days Sales Outstanding is ranked higher than
81% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. PCRX: 35.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
PCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.85  Med: 40.64 Max: 67.76
Current: 35.17
29.85
67.76
Days Payable 49.66
PCRX's Days Payable is ranked lower than
83% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. PCRX: 49.66 )
Ranked among companies with meaningful Days Payable only.
PCRX' s Days Payable Range Over the Past 10 Years
Min: 20.45  Med: 44.4 Max: 246.51
Current: 49.66
20.45
246.51

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.70
PCRX's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. PCRX: -3.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -288.4  Med: -138 Max: -3.7
Current: -3.7
-288.4
-3.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 75.33
PCRX's Price-to-Net-Current-Asset-Value is ranked lower than
78% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. PCRX: 75.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PCRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 10.03  Med: 33.98 Max: 414.29
Current: 75.33
10.03
414.29
Price-to-Tangible-Book 8.80
PCRX's Price-to-Tangible-Book is ranked lower than
77% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. PCRX: 8.80 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PCRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.1  Med: 10.49 Max: 99.7
Current: 8.8
5.1
99.7
Price-to-Median-PS-Value 0.57
PCRX's Price-to-Median-PS-Value is ranked higher than
92% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. PCRX: 0.57 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PCRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 1.1 Max: 2.29
Current: 0.57
0.04
2.29
Earnings Yield (Greenblatt) % -2.15
PCRX's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. PCRX: -2.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PCRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -72.7  Med: -2.8 Max: 1.2
Current: -2.15
-72.7
1.2

More Statistics

Revenue (TTM) (Mil) $280.45
EPS (TTM) $ -1.31
Beta1.85
Short Percentage of Float13.46%
52-Week Range $29.81 - 58.95
Shares Outstanding (Mil)40.57

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 285 316 372 442
EPS ($) -0.10 0.53 1.35 1.93
EPS without NRI ($) -0.10 0.53 1.35 1.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}